Introduction
Cyclosporine A (CsA)-alone or in combination with methotrexate is widely used for graft-versus-host disease (GVHD) prophylaxis among haematopoietic allogeneic stem cell transplant (HSCT) recipients. 1 CsA binds to the cyclophilin of lymphocytes resulting in calcineurin inhibition which, in turn, leads to reduced interleukin-2 (IL-2) levels and inhibition of T-lymphocyte proliferation. The CsA acts in a concentration-dependent rather than a timedependent fashion and it has been shown that the greatest pharmacodynamic effect occurs within the first 2 h of exposure (C 2 ) at peak CsA levels of 800-2285 mg/l which result in 70-96% calcineurin inhibition and maximum suppression of IL-2 release from T cells.
2,3 C 2 monitoring has been adopted for renal, liver and heart transplant recipients as the 2 h peak concentration correlates well with the area under the concentration-time curve (AUC) from 0 to 4 h after giving the drug and that this predicts the occurrence of acute rejection and nephrotoxicity. C 2 monitoring is also associated with clinical benefits like a reduction in graft rejections after solid organ transplantation. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Surprisingly, data on pharmacokinetics and target C 2 levels are lacking in HSCT patients. Moreover, there is no consensus about how CsA should be administered with some centres giving 1 or 2 intermittent infusions and others continuous 24 h infusion. 1 Hence, we decided to determine whether administering CsA at a daily dose of 3 mg/kg/day intravenously (i.v.) in 2 h (short infusion) twice-daily achieved C 2 blood levels of at least 800 mg/l and whether it was feasible and safe.
Patients and methods

Patients
From June 2001 till August 2002, 22 patients undergoing allogeneic HSCT for various haematological malignancies after myeloablative preparative regimens gave their informed consent to participate in the study. Subjects were eligible if they were aged between 18 and 65 years, were to receive an HLA-matched, MLC-negative, partial T-cell depleted (98%) allogeneic HSCT, had never been exposed to cyclosporine before. Patients were excluded if they had a body mass index (BMI) above 30 kg/m 2 , had received systemically active azoles within the 2 weeks before HSCT or had elevated serum creatinine levels in excess of 220 mmol/l at study entry. On admission a polyurethane quadruple lumen catheter (Arrow-Howes Quad-Lumen Central Venous Catheterization Set with Blue FlexTip Catheter, Arrow International, Reading, USA) was inserted in the right or left subclavian vein. Antimicrobial prophylaxis and therapy was given in accordance with our standard of care. All patients received ciprofloxacin 500 mg b.i.d. orally as prophylaxis. This was stopped and changed to meropenem 1 g t.i.d. i.v. the day after transplant and continued until the end of neutropenia. Fluconazole 200 mg once daily was only given to patients shown to be colonized with susceptible Candida species. No other azole antifungal agents were given as prophylaxis.
Study design
The study was approved by the Ethics Committee and was an open crossover study in which half of the trial subjects were to receive cyclosporine 1.5 mg/kg/day by continuous infusion over 12 h twice daily for the first 7 days then by a 2-h infusion of the same dose twice daily for the next 7 days (Group A). The other half of the trial subjects were to receive the same dose of cyclosporine by a 2-h infusion twice daily for the first 7 days then by continuous infusion over 12 h twice daily for the next 7 days (Group B).
A random allocation list was prepared by the pharmacist before inclusion of the first patient started and each individual treatment allocation was placed in a series of sequential, numbered sealed envelopes. The pharmacist was contacted once a patient fulfilled all the inclusion and exclusion criteria and the next consecutive envelope was opened to reveal the treatment group that had been allocated. Administration of CsA began on the day of transplant (study day 1) with the drug being given exclusively via the medial lumen twice daily at 0900 and 2100 hours.
Cyclosporine blood level monitoring: C 2 and AUC After discarding the first 5 ml of blood, blood samples of 10 ml were drawn via the distal lumen of the catheter on study days 1, 8 and 15 just before the first infusion of CsA (trough level) and 1, 2, 3, 4, 6, 8, 12 and 24 h after to obtain a pharmacokinetic profile on each of these days, according to the method described by Luke et al.
14 CsA blood concentrations were measured using a monoclonal whole blood assay (TDx Abbott Laboratories, North Chicago, IL, USA). This assay detects 25-1500 mg/l of CsA with a coefficient variation of less than 4%.
Safety
Laboratory measurements were performed daily and included creatinine, electrolytes, glucose and liver function tests. Serum protein and magnesium were measured twice weekly. Serum creatinine was also scored using the method described by Lindholm et al., 15 which considers an increase of the serum creatinine value greater than 20% within a 7-day period as nephrotoxicity. Concomitant medication and parenteral fluid administration were recorded. Vital signs and body weight were noted at recruitment and four times daily until day 28. Furosemide was given when the body weight increased by 42 kg over the admission weight. The Common Terminology Criteria for Adverse Events v3.0 (CTC) were used to score adverse events. Each patient was followed for up to 3 months after starting CsA to enable registration of major transplant-related complications as acute GVHD according to the Glucksberg criteria 16 or death.
Statistical analysis
The Student's two-tailed t-test was used to compare numerical data and the w 2 -test was used to compare frequencies of toxicity as scored by the CTC criteria between the two groups. This test was also used to compare differences in the occurrence of direct CsA infusion-related side effect that is all blood samples taken at the correct time and no CsA levels exceeding 1500 mg/l. The AUC 0-4 h and its relationship to CsA levels at 1 h (C 1 ) , 2 h (C 2 ) and 3 h (C 3 ) after starting the 2-h infusion was analysed using Prism 4 software (Graphpad Software Inc). P-values o0.05 were considered statistically significant.
Results
One patient was excluded because of prior azole drug usage. The characteristics at study entry of each group were similar and age, protein levels and BMI were comparable (Table 1) .
Cyclosporine blood level monitoring: C 2 levels and AUC 0-4 h In group A, nine out of 33 profiles were excluded from analysis because CsA was not infused exactly as described in the study protocol (n ¼ 5) or because of missing blood samples (n ¼ 4). In group B, seven out of 30 profiles were excluded because CsA was not infused exactly as described in the study protocol (n ¼ 5) or because of missing blood samples (n ¼ 2). To illustrate the difference of profiles generated during CsA short infusion and continuous infusion respectively, two evaluable profiles are shown in Figure 1 . In total, eight pharmacokinetic profiles were obtained after continuous infusion from patients in group A on day 1 and a further eight and seven, respectively, were obtained from patients in group B on days 8 and 15. Levels exceeding 800 mg/l were found in only three of 23 cases. By contrast 20 out of 24 available pharmacokinetic profiles following 2 h infusion showed a C 2 X800 mg/l (eight on day 1 from group B and nine and seven, respectively, on days 8 and 15 from Group A). The four patients who received CsA short infusions and did not achieve C 2 levels X800 mg/l had C 2 levels of 659, 684, 773 and 784 mg/l.
Fifteen profiles were available for C 2 -analysis for six, six and three patients, respectively, on days 1, 8 and 15 after the 2-h infusion. C 2 levels of CsA correlated better than did either C 1 or C 3 with the AUC 0-4 h (r 2 ¼ 0.62: Figure 2 ).
Concomitant drugs
Six patients in group A and four in group B were given fluconazole as prophylaxis. One patient in group A and two in Group B were given metoclopramide. No other drugs known to interact with cyclosporine were given during the study period.
Incidence of acute GVHD
Fifteen out of 21 (71%) patients developed acute GVHD of the skin, from which eight had grade 2 or higher.
Safety
Infusion-related side effects. Patients who received CsA in 2-h infusions did not experience significantly more adverse events than those who were given the drug continuously (Table 2 ). In the second study week 5 patients who had received short infusions and 1 patient given continuous infusion reported a burning sensation of hands or feet during CsA administration. This was not a significant difference (P ¼ 0.072) although it was the reason why one patient declined further short infusions of the drug.
Noninfusion-related side effects. There were no significant differences between the 2 h administration and continuous infusion in nephrotoxicity or hepatotoxicity except that gGT, which was significantly higher (CTC-NCIC toxicity grade X2) during the first week of study (P ¼ 0.031) in the group that received CsA continuously. One patient in Group A experienced severe neurotoxicity CTC grade X2 that progressed to toxic-metabolic encephalopathy starting from day 8. This patient died on day 37 of respiratory insufficiency and acute GVHD. Another patient in Group B was readmitted on day 28 because of acute kidney failure (creatinine 575 mmol/l), which disappeared after interrupting treatment with CsA. In the second week of the study catheter-related vena subclavian thrombosis CTC grade X2 was diagnosed in four cases all in Group A (P ¼ 0.034). This was unlikely the result of the short infusion of CsA though no other plausible explanation could be found.
Discussion
This study shows that CsA short infusions can safely induce C 2 concentrations X800 mg/l in HSCT recipients.
Moreover, C 2 correlates well with the AUC 0-4 h which is a good indicator of exposure. Although CsA has been used routinely for prevention of GVHD (and graft rejection) in solid organ and stem cell transplantations since the early 1980s, it is still not known which dose and duration of treatment is optimal for HSCT recipients. Ruutu et al. reported wide variation regarding CsA usage for prophylaxis and treatment of GVHD in a survey of 87 European Bone Marrow Transplant Centres. As a case in point, they found an initial median dose of 3 mg/kg CsA given i.v. with a range of 1-20 mg/kg. 1 As previously stated, maximal suppression of IL-2 release from T-cells occurs within the first 2 h after CsA administration. Therefore, achieving a CsA peak concentration by infusing CsA 3 mg/kg in 2 h twice daily seems more rational than giving the drug by continuous infusion of 24 h.
The narrow therapeutic index of CsA makes it important to evaluate the real CsA dose a patient is exposed to. This is best represented by the AUC 0-4 h which in turn is most accurately predicted by CsA C 2 levels. In renal, liver and heart transplant patients, there is already increasing evidence that C 2 not only correlates well with the AUC 0-4 h , and that C 2 monitoring to ensure adequate levels resulted in lower incidences of rejection and nephrotoxicity. [4] [5] [6] [7] [8] 10, 12, 13 Unfortunately, there are no data to our knowledge about C2 monitoring among HSCT recipients. In our study, short infusion of CsA resulted in C2 levels X800 mg/l in 20 of 24 (83%) patients. CsA samples were drawn through a multiple lumen polyurethane CVC which we had shown previously to be as reliable as drawing samples by venepuncture. 17 The incidence of acute GVHD of the skin we noted in this study is to be expected in T-cell-depleted allogeneic HLA-matched HSCT. However, analogous to the reduction of graft rejection and toxicity in kidney transplant patients, a reduction in GVHD in HSCT recipients can be expected if CsA dose will be adjusted to C 2 levels.
This pilot study showed that C 2 levels X800 mg/l can be achieved by giving 3 mg/kg/day CsA in two divided doses i.v. in a 2 h infusion and that there was no significant difference in the incidence side effects or toxicity between the this mode of administration and the same dose given over 24 h by continuous infusion. We have now adopted this scheme and recommend increasing the dose of CsA if C 2 levels of X800 mg/l are not achieved as this correlates best with good exposure. However further investigation is clearly necessary in order to establish if C 2 monitoring among HSCT recipients leads to the improved engrafting, decreased rejection, lower incidence of GVHD and less toxicity as has been shown for kidney, liver and heart transplant recipients.
